Central Nervous System Therapeutics Market Report 2035

What Is The Present Market Size Of The Central Nervous System Therapeutics Market, And At What Annual Growth Rate Is It Expanding?
The central nervous system therapeutics market size has grown strongly in recent years. It will grow from $134.99 billion in 2025 to $147.29 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing burden of depression and epilepsy, growing aging population, limited treatment options for degenerative disorders, rising hospitalization rates for cns conditions, expansion of hospital and clinic infrastructure.

The central nervous system therapeutics market size is expected to see strong growth in the next few years. It will grow to $206.68 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to development of novel neuroprotective agents, growth in biologics and gene-based therapies, increasing investment in neuroscience research, rising adoption of personalized medicine, expanding access to cns treatments in emerging markets. Major trends in the forecast period include rising prevalence of neurological and mental health disorders, growing adoption of combination therapies for cns diseases, increasing focus on long-term disease management and symptom control, expansion of homecare-based cns treatment solutions, improved drug formulations with better blood-brain barrier penetration.

Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp

What Key Drivers Are Primarily Contributing To The Growth Of The Central Nervous System Therapeutics Market?
The increasing prevalence of mental health disorders is expected to propel the growth of the central nervous system therapeutics market going forward. Mental health disorders refer to a wide range of conditions that affect a person’s thinking, feeling, behavior, or mood, such as depression, anxiety disorders, schizophrenia, and bipolar disorder. The rising prevalence of mental health disorders is due to increasing exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to conditions such as anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics help treat mental health disorders by targeting brain chemicals and neural pathways involved in mood, behavior, and cognition. For instance, in December 2025, according to the report published by Bristol City Council, a UK-based local government authority, in Bristol, 66,815 patients aged 18 and over were recorded on GP practice depression registers in 2022-23, marking a 6.0% rise from 2021-22. Therefore, the increasing prevalence of mental health disorders is driving the growth of the central nervous system therapeutics market.

What Are The Essential Segmentation Layers Examined Within The Central Nervous System Therapeutics Market?
The central nervous system therapeutics market covered in this report is segmented –

1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes
2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
4) By Application: Hospital, Clinic, Homecare, Other Applications

Subsegments:
1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics
2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents
3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids
4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives
5) By Pain Relievers: Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief
6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

What New Trends Are Beginning To Take Shape Within The Central Nervous System Therapeutics Market?
Major companies operating in the central nervous system therapeutics market are focusing on developing innovative solutions such as capsid engineering to enhance targeted gene delivery, therapeutic efficacy, and blood-brain barrier penetration for improved treatment of neurological disorders. Capsid engineering refers to the modification and optimization of the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), used in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, launched coAAV CSF 01, a novel adeno associated virus (AAV) for central nervous system (CNS) delivery using their proprietary ALIGATER platform. It demonstrated significantly enhanced transduction efficiency and safety compared to AAV9. When delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Remarkably, equivalent expression levels to AAV9 were attained at just one-fifth of the dose, highlighting its superior potency. Additionally, the vector showed substantially reduced off-target expression in peripheral organs such as the liver while maintaining a favorable safety profile, including preserved peripheral nerve integrity. These results underscore the vector’s potential to enhance CNS gene therapy outcomes with improved precision and lower systemic risk.

Who Are The Prominent Industry Participants Shaping The Central Nervous System Therapeutics Market?
Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.

Get Your In-Depth Central Nervous System Therapeutics Market Report Now:
https://www.thebusinessresearchcompany.com/report/central-nervous-system-therapeutics-global-market-report

What Are The Fastest-Expanding Regions Contributing To The Growth Of The Central Nervous System Therapeutics Market?
North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company